Abstract
Purpose
21-hydroxylase deficiency (21-OHD) is a congenital adrenal disease with more than 200 mutations published to date. The aim of this report is to describe a severe novel mutation of the CYP21A2 gene.
Method
We describe a case of a 39-year-old male diagnosed with a salt wasting congenital adrenal hyperplasia (SWCAH) due to 21-OHD. The genetic testing was done using a combination of three methods (PCR XL, SALSA-MLPA, and bidirectional sequencing) and finally an in silico analysis.
Results
The genetic testing demonstrated three severe mutations of the CYP21A2 gene (p.Gln318*; c.290-13C>G; and p.Trp86*), being the last one a novel mutation not previously reported. The in silico modeling of the p.Trp86* (c.258G>A) showed a truncated CYP21A2 protein that loses all the main structural features required for activity, such as the HEM binding domain and the hormone binding site.
Conclusion
We present an adult man with an SWCAH due to 21-OHD who carried three severe mutations of the CYP21A2 gene, one of them, p.Trp86* (c.258G>A) has not been previously described.
Similar content being viewed by others
References
D. El-Maouche, W. Arlt, D.P. Merke, Congenital adrenal hyperplasia. Lancet 390, 2194–2210 (2017)
P.W. Speiser, W. Arlt, R.J. Auchus, L.S. Baskin, G.S. Conway, D.P. Merke et al. Congenital adrenal hyperplasia due to steroid 21-Hydroxylase deficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 103, 4043–4088 (2018)
F. Hannah-Shmouni, W. Chen, D.P. Merke, Genetics of congenital adrenal hyperplasia. Endocrinol. Metab. Clin. North Am. 46, 435–458 (2017)
B.L. Therrell, S.A. Berenbaum, V. Manter-Kapanke, J. Simmank, K. Korman, L. Prentice et al. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics 101, 583–590 (1998)
P.W. Speiser, R. Azziz, L.S. Baskin, L. Ghizzoni, T.W. Hensle, D.P. Merke et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 95, 4133–4160 (2010)
P.W. Speiser, B. Dupont, P. Rubinstein, A. Piazza, A. Kastelan, M.I. New, High frequency of nonclassical steroid 21-hydroxylase deficiency. Am. J. Hum. Genet. 37, 650–667 (1985)
D.W. Nebert, D.R. Nelson, M.J. Coon, R.W. Estabrook, R. Feyereisen, Y. Fujii-Kuriyama et al. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol. 10, 1–14 (1991)
P.W. Speiser, P.C. White, Congenital adrenal hyperplasia. N. Engl. J. Med. 349, 776–788 (2003)
Z. Vrzalová, Z. Hrubá, E.S. Hrabincová, S. Vrábelová, F. Votava, S. Koloušková et al. Chimeric CYP21A1P/CYP21A2 genes identified in Czech patients with congenital adrenal hyperplasia. Eur. J. Med. Genet. 54, 112–117 (2011)
P.W. Speiser, J. Dupont, D. Zhu, J. Serrat, M. Buegeleisen, M.T. Tusie-Luna et al. Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J. Clin. Investig. 90, 584–595 (1992)
M.I. New, M. Abraham, B. Gonzalez, M. Dumic, M. Razzaghy-Azar, D. Chitayat et al. Genotype–phenotype correlation in 1507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Proc. Natl. Acad. Sci. Usa. 110, 2611–2616 (2013)
P. Concolino, A. Costella, Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency: a comprehensive focus on 233 pathogenic variants of CYP21A2 gene. Mol. Diagn. Ther. 22, 261–280 (2018)
D. Keen-Kim, J.B. Redman, R.U. Alanes, M.M. Eachus, R.C. Wilson, M.I. New et al. Validation and clinical application of a locus-specific polymerase chain reaction- and minisequencing-based assay for congenital adrenal hyperplasia (21-hydroxylase deficiency). J. Mol. Diagn. 7, 236–246 (2005)
A. Wedell, E.M. Ritzen, B. Haglund-Stengler, H. Luthman, Steroid 21-hydroxylase deficiency: three additional mutated alleles and establishment of phenotype-genotype relationships of common mutations. Proc. Natl Acad. Sci. USA. 89, 7232–7236 (1992)
A. Sali, T.L. Blundell, Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779–815 (1993)
P.S. Pallan, C. Wang, L. Lei, F.K. Yoshimoto, R.J. Auchus, M.R. Waterman et al. Human cytochrome P450 21A2, the major steroid 21-Hydroxylase: structure of the enzyme, progesterone substrate and rate-limiting C-H bond cleavage. J. Biol. Chem. 290, 13128–13143 (2015)
Q.S. Zhao, S. Modi, G. Smith, M. Paine, P. McDonagh, P.D. Wolf, et al., Crystal structure of the FMN-binding domain of human cytochrome P450 reductase at 1.93 Å resolution. Protein Sci. 8, 298–306 (1999)
D. Kozakov, D.R. Hall, B. Xia, K.A. Porter, D. Padhorny, C. Yueh et al. The ClusPro web server for protein–protein docking. Nat. Protoc. 12, 255–278 (2017)
S.R. Comeau, D.W. Gatchell, S. Vajda, C.J. Camacho, ClusPro: an automated docking and discrimination method for the prediction of protein complexes. Bioinformatics 20, 45–50 (2004)
B.R. Brooks, C.L. Brooks 3rd, A.D. Mackerell Jr, L. Nilsson, R.J. Petrella, B. Roux et al. CHARMM: the biomolecular simulation program. J. Comput. Chem. 30, 1545–1614 (2009)
J.M. Schwarz, C. Rödelsperger, M. Schuelke, D. Seelow, MutationTaster evaluates disease-causing potential of sequence alterations. Nat. Methods 7, 575–576 (2010)
Y. Choi, A.P. Chan, PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. Bioinformatics 31, 2745–2747 (2015)
M. Mort, T. Sterne-Weiler, B. Li, E.V. Ball, D.N. Cooper, P. Radivojac et al. MutPred Splice: machine learning-based prediction of exonic variants that disrupt splicing. Genome Biol. 15, R19 (2014)
I.A. Adzhubei, S. Schmidt, L. Peshkin, V.E. Ramensky, A. Gerasimova, P. Bork et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248–249 (2010)
C.E. Fardella, H. Poggi, P. Pineda, J. Soto, I. Torrealba, A. Cattani et al. Salt-wasting congenital adrenal hyperplasia: detection of mutations in CYP21B gene in a Chilean population. J. Clin. Endocrinol. Metab. 83, 3357–3360 (1998)
E. Mornet, J.F. Gibrat, A 3D model of human P450c21: study of the putative effects of steroid 21-hydroxylase gene mutations. Hum. Genet. 106, 330–339 (2000)
M. Janner, A.V. Pandey, P.E. Mullis, C.E. Flück, J. Marco, V.P. Amit, E.M. Primus, E.F.C. Christa, Clinical and biochemical description of a novel CYP21A2 gene mutation 962_963insA using a new 3D model for the P450c21 protein. Eur. J. Endocrinol. 155, 143–151 (2006)
S. Haider, B. Islam, V. D’Atri, M. Sgobba, C. Poojari, L. Sun et al. Structure–phenotype correlations of human CYP21A2 mutations in congenital adrenal hyperplasia. Proc. Natl Acad. Sci. USA 110, 2605–2610 (2013)
C. Wang, P.S. Pallan, W. Zhang, L. Lei, F.K. Yoshimoto, M.R. Waterman, Functional analysis of human cytochrome P450 21A2 variants involved in congenital adrenal hyperplasia. J. Biol. Chem. 292, 10767–10778 (2017)
P.S. Pallan, L. Lei, C. Wang, M.R. Waterman, F.P. Guengerich, M. Egli, Research resource: correlating human cytochrome P450 21A2 crystal structure and phenotypes of mutations in congenital adrenal hyperplasia. Mol. Endocrinol. 29, 1375–1384 (2015)
Acknowledgements
Catalina Tobar, MD for presenting this case report to the national annual meeting of endocrinology in Chile.
Funding
Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT) Project Number 1160695, IMII P09/016-F.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in the study were in accordance with the ethical standards of the Ethical Review Board of the School of Medicine of the Pontificia Universidad Católica de Chile and with the 1964 Helsinki declaration.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Arteaga, E., Valenzuela, F., Lagos, C.F. et al. Detection of a novel severe mutation affecting the CYP21A2 gene in a Chilean male with salt wasting congenital adrenal hyperplasia. Endocrine 67, 258–263 (2020). https://doi.org/10.1007/s12020-019-02097-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-019-02097-3